Strong Early Momentum for LIVMARLI Sets Stage for Active 2022 for Mirum Pharamceuticals (MIRM) - H.C. Wainwright
Tweet Send to a Friend
H.C. Wainwright analyst Ed Arce reiterated a Buy rating and $64 price target on Mirum Pharamceuticals (NASDAQ: MIRM), following a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
